91 episodes
Avalere Essential Voice Avalere
-
- Health & Fitness
Twenty years ago, Avalere set out to be the essential voice in improving healthcare. Rest your eyes or use your commute time to listen to our experts discuss the hot topics that you need to track.
-
RSV Prevention, Part IV: Immunocompromised Populations
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
-
RSV Prevention, Part III: Older Adult Vaccination
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.
-
RSV Prevention, Part II: Pediatric Vaccines and Maternal immunization
Tune into the second episode in our miniseries focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
-
RSV Prevention, Part I: Pediatric Monoclonal Antibodies
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
-
NCDs, Part III: Agency Mandates, Decisions, Coverage and Access
Tune into the third episode in the Avalere Health Essential Voice podcast series focused on Agency decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs) by considering how potential policy and market catalysts 3 to 5 years out may help stakeholders think through opportunities and risks at key decision points ranging from early in development to implications for Part D.
-
NCDs, Part II: Evidence Development to Fulfill CED Requirements
Tune into the second episode in the Avalere Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS’s evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.